These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35912188)

  • 1. Stable
    Chilà R; Chiappa M; Guffanti F; Panini N; Conconi D; Rinaldi A; Cascione L; Bertoni F; Fratelli M; Damia G
    Front Oncol; 2022; 12():903536. PubMed ID: 35912188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
    Ekumi KM; Paculova H; Lenasi T; Pospichalova V; Bösken CA; Rybarikova J; Bryja V; Geyer M; Blazek D; Barboric M
    Nucleic Acids Res; 2015 Mar; 43(5):2575-89. PubMed ID: 25712099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
    Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
    J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
    Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
    Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
    Dubbury SJ; Boutz PL; Sharp PA
    Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK12: an emerging therapeutic target for cancer.
    Lui GYL; Grandori C; Kemp CJ
    J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
    Vrábel D; Svoboda M; Navrátil J; Kohoutek J
    Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
    Bajrami I; Frankum JR; Konde A; Miller RE; Rehman FL; Brough R; Campbell J; Sims D; Rafiq R; Hooper S; Chen L; Kozarewa I; Assiotis I; Fenwick K; Natrajan R; Lord CJ; Ashworth A
    Cancer Res; 2014 Jan; 74(1):287-97. PubMed ID: 24240700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.
    Liu Y; Hao M; Leggett AL; Gao Y; Ficarro SB; Che J; He Z; Olson CM; Marto JA; Kwiatkowski NP; Zhang T; Gray NS
    J Med Chem; 2020 Jul; 63(13):6708-6726. PubMed ID: 32502343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging roles of CDK12 in tumorigenesis.
    Paculová H; Kohoutek J
    Cell Div; 2017; 12():7. PubMed ID: 29090014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
    Choi SH; Kim S; Jones KA
    Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th e role of CDK12 in tumor bio logy.
    Dzimková M; Procházková J; Klát J; Kohoutek J
    Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RIP1 promotes proliferation through G2/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells.
    Zheng XL; Yang JJ; Wang YY; Li Q; Song YP; Su M; Li JK; Zhang L; Li ZP; Zhou B; Lin Y
    Acta Pharmacol Sin; 2020 Sep; 41(9):1223-1233. PubMed ID: 32242118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
    Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K; Rocconi RP
    PLoS One; 2014; 9(9):e107142. PubMed ID: 25216266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cdk12 Is A Gene-Selective RNA Polymerase II Kinase That Regulates a Subset of the Transcriptome, Including Nrf2 Target Genes.
    Li X; Chatterjee N; Spirohn K; Boutros M; Bohmann D
    Sci Rep; 2016 Feb; 6():21455. PubMed ID: 26911346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
    Naidoo K; Wai PT; Maguire SL; Daley F; Haider S; Kriplani D; Campbell J; Mirza H; Grigoriadis A; Tutt A; Moseley PM; Abdel-Fatah TMA; Chan SYT; Madhusudan S; Rhaka EA; Ellis IO; Lord CJ; Yuan Y; Green AR; Natrajan R
    Mol Cancer Ther; 2018 Jan; 17(1):306-315. PubMed ID: 29133620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.
    Guffanti F; Fratelli M; Ganzinelli M; Bolis M; Ricci F; Bizzaro F; Chilà R; Sina FP; Fruscio R; Lupia M; Cavallaro U; Cappelletti MR; Generali D; Giavazzi R; Damia G
    Oncotarget; 2018 May; 9(37):24707-24717. PubMed ID: 29872499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Wang C; Wang H; Lieftink C; du Chatinier A; Gao D; Jin G; Jin H; Beijersbergen RL; Qin W; Bernards R
    Gut; 2020 Apr; 69(4):727-736. PubMed ID: 31519701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.